WASHINGTON — Only two years ago, Michelle McMurry-Heath was named chief executive of BIO, the world’s largest biotech trade organization. She was hailed by her predecessor as a “great leader.”
So her swift and abrupt exit from the role earlier this month shocked the industry. But it was set in motion in late summer, when the Biotechnology Innovation Organization’s board of directors dispatched an outside firm to produce an “assessment” of her performance. The firm interviewed 35 employees.
When McMurry-Heath saw the final report, she decided to resign.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect